Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) Liabilities and Shareholders Equity (2020 - 2023)

Terns Pharmaceuticals' Liabilities and Shareholders Equity history spans 4 years, with the latest figure at $271.7 million for Q3 2023.

  • For Q3 2023, Liabilities and Shareholders Equity rose 41.07% year-over-year to $271.7 million; the TTM value through Dec 2023 reached $862.7 million, up 10.44%, while the annual FY2022 figure was $287.0 million, 70.78% up from the prior year.
  • Liabilities and Shareholders Equity reached $271.7 million in Q3 2023 per TERN's latest filing, down from $289.7 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $301.3 million in Q1 2023 to a low of $92.3 million in Q4 2020.
  • Average Liabilities and Shareholders Equity over 4 years is $205.9 million, with a median of $190.3 million recorded in 2021.
  • Peak YoY movement for Liabilities and Shareholders Equity: decreased 22.95% in 2022, then skyrocketed 99.98% in 2023.
  • A 4-year view of Liabilities and Shareholders Equity shows it stood at $92.3 million in 2020, then surged by 82.11% to $168.1 million in 2021, then surged by 70.78% to $287.0 million in 2022, then decreased by 5.34% to $271.7 million in 2023.
  • Per Business Quant, the three most recent readings for TERN's Liabilities and Shareholders Equity are $271.7 million (Q3 2023), $289.7 million (Q2 2023), and $301.3 million (Q1 2023).